Robert Kribs, MD
Hematology · Kansas City, KSNPI 1952797409
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $724 of the $824 with a category attached, or 87.9%. 8 manufacturers reported payments, led by Sanofi at 55.9% of the total. Reporting peaked in 2024 at $339 and has fallen 52.7% since, to $160 in 2025.
Across 11 payments — averaging $74.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$460
- Incyte Corporation$125
- Sanofi-aventis U.S. LLC$100
- Genentech USA, Inc.$35
- Genetix Biotherapeutics Inc$31
- Gilead$29
- plus $44 from 2 others
Across 3 payments — averaging $6450.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rigel Pharmaceuticals, Inc.$19K
What the payments were for
- Food & beverage$72488%
- Education$10012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 4 | $460 |
| Incyte Corporation | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Genentech USA, Inc. | 1 | $35 |
| Genetix Biotherapeutics Inc | 1 | $31 |
| Gilead | 1 | $29 |
| Global Blood Therapeutics, Inc. | 1 | $25 |
| Sobi, Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 34 | $445,109 |
| DopteletAvatrombopag Maleate | 16 | $284,289 |
| TavalisseFostamatinib Disodium | 14 | $193,540 |
| EliquisApixaban | 90 | $99,402 |
| OxycontinOxycodone Hcl | 43 | $50,553 |
| Xtampza ErOxycodone Myristate | 79 | $38,845 |
| XareltoRivaroxaban | 31 | $31,942 |
| Enoxaparin Sodium | 22 | $6,185 |
| Oxycodone Hcl | 287 | $5,903 |
| Fentanyl | 11 | $2,775 |
| Hydroxyurea | 39 | $1,701 |
| Morphine Sulfate ErMorphine Sulfate | 42 | $1,048 |
| Tizanidine Hcl | 20 | $988 |
| Morphine Sulfate | 16 | $549 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $459 |
Paid to pharmacies, not to this prescriber.
Other hematology in Kansas City
- Konstantine HalkidisKansas City$16K
- Barry SkikneKansas City$4K
- Nausheen AhmedWestwood$61K
- Aung TunWestwood$17K
- Forat LutfiWestwood$12K
- Edwin PetrikTopeka$779
- Alma HabibWestwood$369
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.